Loading
NASDAQHealthcareMedical - Instruments & Supplies
Latest quote
$1.69
−$0.21 · -11.05%
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Latest quote
$1.69
−$0.21 · -11.05%
After-hours
$1.70
+$0.01 · +0.59%
Oct 9, 7:31 PM ET
Regular session · ET · Market data may be delayed.
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Day range
Current $1.69
52-week range
Current $1.69
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
22
Expensive
Sentiment
50
Mixed
Risk
60
Elevated Risk
Momentum
49
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Cuprina Holdings (Cayman) Limited is a Singaporean biotechnology and biomedical enterprise, primarily dedicated to pioneering and bringing to market advanced solutions for the management of persistent wounds. The company produces and supplies its flagship MEDIFLY brand, which features medical-grade sterile blowfly larvae bio-dressing products designed to function as an effective biological debridement tool for chronic wounds. Beyond its core wound care business, Cuprina also extends its operations into the broader health and beauty market, where it provides a range of cosmeceutical items.
Day range
Current $1.69
52-week range
Current $1.69
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (SGD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 49.89K SGD | 48.32K SGD | 100.77K SGD | 56.6K SGD | 58.5K SGD |
| Cost of goods sold | 50.54K SGD | 51.35K SGD | 64.17K SGD | 36.62K SGD | 35.45K SGD |
| Gross profit | −645 SGD | −3.02K SGD | 36.61K SGD | 19.98K SGD | 23.06K SGD |
| Research and development | 226.88K SGD | 241.36K SGD | 167.73K SGD | 292.88K SGD | 279.79K SGD |
| Selling, general, and administrative | 4.39M SGD | 1.27M SGD | 833.45K SGD | 830.36K SGD | 248.19K SGD |
| Operating expenses | 4.57M SGD | 1.64M SGD | 1.1M SGD | 1.2M SGD | 575.81K SGD |
| Interest income | 26.56K SGD | — | — | — | — |
| Interest expense | 14.72K SGD | 37.21K SGD | 56.59K SGD | 2.02K SGD | 2.78K SGD |
| Depreciation and amortization | 36.52K SGD | 42.19K SGD | 35.06K SGD | 29.09K SGD | 27.46K SGD |
| Operating income | −4.57M SGD | −1.65M SGD | −1.07M SGD | −1.18M SGD | −552.75K SGD |
| Net income | −4.67M SGD | −1.56M SGD | −1.12M SGD | −1.09M SGD | −519.69K SGD |
Company facts updated Oct 10, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
